Talsaclidine

The clearest single illustration of why the M1 agonist approach kept failing. Talsaclidine did the mechanistic thing it was designed to do; it shifted amyloid precursor protein processing and cut cerebrospinal fluid amyloid beta 42 in real patients. It simply could not be given at a dose that also improved cognition without making people sweat and salivate, and receptor selectivity on paper did not fix that. The programme stopped in 2000, and the people who ran it said so plainly.

The dose-limiting toxicity is cholinergic and peripheral, but it is not the one cholinesterase inhibitors produce. Gastrointestinal effects such as nausea and vomiting, largely M3-mediated, were not what stopped escalation; sweating and hypersalivation were, in healthy volunteers and in Alzheimer's patients alike ^[1]. In single-dose phase 1 work, increased salivary secretion was reported from 40 mg upward, heart rate rose from 80 mg, and between 100 and 160 mg volunteers reported urinary urgency and burning on urination, lacrimation, nasal secretion, accommodation disturbance, heartburn, cramps, nausea, diarrhoea, sweating and palpitations ^[9]. In aged rhesus monkeys, 4.7 mg/kg produced lethargy and heavy drooling in some animals ^[7]. Long-term human safety was never established; the open-label extension study that would have generated it was terminated before completion.

Talsaclidine, known in development as WAL 2014 and as its fumarate salt WAL 2014 FU, came from Boehringer Ingelheim and received its USAN in 1995. Phase 1 work ran through 1998 and 1999, including single-dose, multiple-dose and radiolabelled mass-balance studies.

Three trials in mild to moderate dementia of the Alzheimer type followed in 1999 and 2000: a 362 patient, twelve week, double-blind placebo-controlled dose ranging study at 6, 12, 24 and 36 mg three times daily, which completed (NCT02249403); a higher dose panel study at 48 and 60 mg three times daily that enrolled 54 of a planned 150 and was terminated (NCT02249351); and an open-label long-term safety follow-up at 24 mg three times daily that enrolled 198 and was also terminated (NCT02248116).

The company's own published account of the outcome is blunt: neither talsaclidine nor sabcomeline showed convincing improvement of cognitive function in mild to moderate Alzheimer's disease, and its authors called for a reassessment of the muscarinic hypothesis.

Inside the field talsaclidine is remembered less as a failure than as a useful negative result. Together with sabcomeline it is the evidence usually cited for why first-generation M1 agonists could not be dosed to efficacy, and that conclusion is what pushed the field toward allosteric modulators and toward pairing an agonist with a peripherally restricted antimuscarinic. It also holds a claim as one of the earliest drugs shown to lower cerebrospinal fluid amyloid beta in living Alzheimer's patients, which is why it still surfaces in amyloid-lowering reviews decades after development stopped. It has no presence outside academic pharmacology and is not obtainable.